Trial Profile
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCl in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Endoxifen (Primary) ; Tamoxifen
- Indications Advanced breast cancer; Bone metastases; HER2 negative breast cancer
- Focus Therapeutic Use
- 14 Feb 2024 Planned End Date changed from 25 May 2024 to 4 Feb 2025.
- 16 Jul 2023 Planned End Date changed from 25 May 2023 to 25 May 2024.
- 16 Mar 2023 Planned End Date changed from 25 May 2022 to 25 May 2023.